Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ZyVersa Therapeutics

< Previous 1 2 Next >
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
From ZyVersa Therapeutics
Via GlobeNewswire
Tickers ZVSA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.